Russia's Enteromix, a personalized mRNA-based cancer vaccine, has demonstrated 100% efficacy and safety in clinical trials, offering a potential breakthrough in cancer treatment. Developed using technology similar to COVID-19 vaccines, it trains the immune system to eliminate cancer cells without serious side effects.